Samikkannu T.,Institute of NeuroImmune Pharmacology |
Rao K.V.K.,Institute of NeuroImmune Pharmacology |
Ding H.,Institute of NeuroImmune Pharmacology |
Agudelo M.,Institute of NeuroImmune Pharmacology |
And 3 more authors.
PLoS ONE | Year: 2014
Arachidonic acid (AA) is known to be increased in HIV infected patients and illicit drug users are linked with severity of viral replication, disease progression, and impaired immune functions. Studies have shown that cocaine accelerates HIV infection and disease progression mediated by immune cells. Dendritic cells (DC) are the first line of antigen presentation and defense against immune dysfunction. However, the role of cocaine use in HIV associated acceleration of AA secretion and its metabolites on immature dendritic cells (IDC) has not been elucidated yet. The aim of this study is to elucidate the mechanism of AA metabolites cyclooxygenase-2 (COX-2), prostaglandin E2 synthetase (PGE2), thromboxane A2 receptor (TBXA2R), cyclopentenone prostaglandins (CyPG), such as 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2), 14-3-3 ζ/δ and 5-lipoxygenase (5-LOX) mediated induction of IDC immune dysfunctions in cocaine using HIV positive patients. The plasma levels of AA, PGE2, 15d-PGJ2, 14-3-3 ζ/δ and IDC intracellular COX-2 and 5-LOX expression were assessed in cocaine users, HIV positive patients, HIV positive cocaine users and normal subjects. Results showed that plasma concentration levels of AA, PGE2 and COX-2, TBXA2R and 5-LOX in IDCs of HIV positive cocaine users were significantly higher whereas 15d-PGJ2 and 14-3-3 ζ/δ were significantly reduced compared to either HIV positive subjects or cocaine users alone. This report demonstrates that AA metabolites are capable of mediating the accelerative effects of cocaine on HIV infection and disease progression. © 2014 Samikkannu et al.
Kaushik A.,Institute of NeuroImmune Pharmacology |
Shah P.,Florida International University |
Vabbina P.K.,Florida International University |
Jayant R.D.,Institute of NeuroImmune Pharmacology |
And 4 more authors.
Analytical Methods | Year: 2016
A label-free detection of beta-amyloid (βA) protein using an electrochemical immunosensor fabricated via immobilizing specific anti-beta-amyloid antibodies (An-βA-Abs) onto an interdigitated electrode of gold (IDE-Au) modified using a self-assembled monolayer (SAM) of dithiobis(succinimidyl propionate) [DTSP] is presented here. The βA has been investigated as a potential biomarker for monitoring Alzheimer's disease (AD), permanent irreversible and progressive brain damage. Thus βA detection at the pM level is of high significance for AD diagnostics. The IDE-Au modification and covalent immobilization of An-βA-Abs onto electrodes were characterized by differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS) as a function of electrical response variation in each step involved in sensor fabrication. The EIS studies confirmed that the developed βA immunosensor is selective and exhibits a detection limit of 10 pM, its detection range varies from 10 pM to 100 nM, and it has a high sensitivity of 11 kω M-1 with a regression coefficient of 0.99. Thus, the developed sensitive and selective immunosensor with the features of the IDE-Au can be integrated with a miniaturized potentiostat (M-P) to develop a sensing system to detect βA for point-of-care (POC) applications for the assessment and management of AD. The bio-informatics gathered from such a system could be useful to make timely therapeutic decisions. © 2016 The Royal Society of Chemistry.
Liu X.,Huazhong University of Science and Technology |
Liu X.,Institute of NeuroImmune Pharmacology |
Chang S.L.,Institute of NeuroImmune Pharmacology |
Chang S.L.,Seton Hall University
Journal of Medical Sciences | Year: 2011
Alcohol use is very common in our lives and has profound effects on our bodies, especially in adolescents and older people. Alcohol can act on multiple neurotransmitter systems. Among them, the dopaminergic system is thought to play a key role in alcohol-related behaviors and alcohol dependence. This review focuses on the relationship between development and aging of the mesolimbic dopaminergic system and alcohol use. © 2011 JMS.
PubMed | Western Carolina University, Temple University, Institute of Neuroimmune Pharmacology and Florida International University
Type: | Journal: Scientific reports | Year: 2016
Least component-based delivery of drug-tagged-nanocarriers across blood-brain-barriers (BBB) will allow site-specific and on-demand release of therapeutics to prevent CNS diseases. We developed a non-invasive magnetically guided delivery of magneto-electric nanocarriers (MENCs), ~20nm, 10mg/kg, across BBB in C57Bl/J mice. Delivered MENCs were uniformly distributed inside the brain, and were non-toxic to brain and other major organs, such as kidney, lung, liver, and spleen, and did not affect hepatic, kidney and neurobehavioral functioning.